Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
This article was originally published in The Pink Sheet Daily
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.
You may also be interested in...
Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.
2014 is not even a week old, but several privately-held companies have made resolutions to enter the public market this year, building on the momentum of a strong IPO market in 2013.
Juno Therapeutics and Moderna Therapeutics both leveraged promising technologies to bring home venture rounds of more than $100 million in recent weeks. Plus news on recent financings by Argos Therapeutics, Xencor, Sitari and 5am Ventures.